Figure 1 from A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer

Matthew T. Campbell, Amishi Y. Shah,Pavlos Msaouel,Nizar M. Tannir,Arlene O. Siefker-Radtke,Ashish M. Kamat,Neema Navai,Colin P.N. Dinney,Priya Rao,Charles C. Guo,Rahul A. Sheth, Aradhana M. Venkatesan,Rebecca S. Tidwell, Shalini S. Yadav,Aidi Gu, Hong Chen, Marc Macaluso,Fei Duan, Sreyashi Basu,Sonali Jindal,Padmanee Sharma

crossref（2024）

引用 0|浏览0

暂无评分

摘要

Flow cytometry of CD38+ immune cells from serially collected blood samples. A, mRCC cohort. B, MIBC cohort. C, NK cells in the mRCC cohort. D, NK cells in the MIBC cohort. EOT, end of treatment; PD3, predose 3; PD4, predose 4; PD7, predose 7; PD8, predose 8; Pre, pretreatment; PS, post–tissue collection.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要